| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total operating expenses | 23,701 | - |
| Loss from operations | -23,701 | - |
| Other income, net | 981 | - |
| Net loss | -22,720 | -16,109 |
| Stock-based compensation | 4,644 | 3,234 |
| Depreciation expense | 729 | 486 |
| Non-cash lease expense | 201 | 132 |
| Amortization of premiums and accretion of discounts on available-for-sale securities, net | 262 | 192 |
| Prepaid expenses and other current and long-term assets, net | -1,767 | -1,164 |
| Accounts payable and accrued liabilities | -10,386 | -10,179 |
| Operating lease liability | -305 | -200 |
| Net cash used in operating activities | -26,332 | -21,664 |
| Purchases of available-for-sale securities | 19,605 | 16,269 |
| Maturities of available-for-sale securities | 18,349 | 9,359 |
| Net cash (used in) provided by investing activities | -1,256 | -6,910 |
| Proceeds from issuance of common stock under employee stock purchase plan | 24 | 24 |
| Net cash provided by financing activities | 24 | 24 |
| Net decrease in cash, cash equivalents and restricted cash | -27,564 | -28,550 |
| Cash and cash equivalents at beginning of period | 49,069 | - |
| Cash and cash equivalents at end of period | 21,505 | - |
Athira Pharma, Inc. (ATHA)
Athira Pharma, Inc. (ATHA)